标题：Evidence of Human Papillomavirus Vaccine Effectiveness in Reducing Genital Warts: An Analysis of California Public Family Planning Administrative Claims Data, 2007–2010
摘要：Because of the rapid development of genital warts (GW) after infection, monitoring GW trends may provide early evidence of population-level human papillomavirus (HPV) vaccine effectiveness. Trends in GW diagnoses were assessed using public family planning administrative data. Between 2007 and 2010, among females younger than 21 years, these diagnoses decreased 35% from 0.94% to 0.61% ( P trend < .001). Decreases were also observed among males younger than 21 years (19%); and among females and males ages 21-25 (10% and 11%, respectively). The diagnoses stabilized or increased among older age groups. HPV vaccine may be preventing GW among young people. Human papillomavirus (HPV) is a common sexually transmitted infection causing genital warts and anogenital and oropharyngeal cancers. 1 An estimated 1.4 million Americans have genital warts (GW). 2 The quadrivalent HPV vaccine, available in the US since June 2006, prevents HPV types 6 and 11, which cause 90% of GW. 3,4 The Advisory Committee on Immunization Practices (ACIP) recommends routine immunization of females and males aged 11 to 12 years with catch-up for females aged 13 to 26 and males aged 13 to 21 years. 5,6 As of 2010, 49% of adolescent females aged 13 to 17 years in the US had received at least 1 of the 3 doses and 32% had received all 3 doses; in California, 56% received at least 1 dose. 7 Additionally, 21% of US females aged 19 to 26 years had received at least 1 dose. 8 In the United States, several approaches are under way to measure the population-based impact of the HPV vaccine. 9,10 Because of the rapid development of GW after infection, monitoring GW trends may provide early evidence of vaccine effectiveness. 11,12 Further, analyses of administrative data enable the monitoring of vaccine-preventable disease outcomes.
